The European Medicines Agency (EMA) has released the minutes from its Herbal Medicinal Products Committee (HMPC) meeting held from 17 to 19 November 2025, published on 28 January 2026. The document opens a window into ongoing deliberations about regulatory frameworks for herbal medicines in the European Union, a sector where patient safety, industry innovation, and market competitiveness often intersect and sometimes clash.
This document is a detailed record of HMPC meeting discussions rather than new legislation. It offers transparent insights into the committee’s evaluations, scientific opinions, and convocations but does not impose direct mandatory provisions. The minutes are intended to inform stakeholders on the state of deliberations and set the stage for future policy initiatives.
The HMPC minutes describe various topics discussed by the committee during their three-day session. These include evaluations of herbal substances, standardization efforts, and safety monitoring practices. The document reveals the EMA’s ongoing balancing act between strengthening consumer protection—through rigorous assessment of herbal medicinal products—and preserving the competitiveness of EU herbal product manufacturers by streamlining regulatory pathways and offering clearer guidelines.
enhancing regulatory oversight in herbal medicine (increasing EU authority and supervision), pursuing harmonization across member states (supporting EU integration over national sovereignty in this sector), and accommodating both rigorous safety standards and industry-friendly compliance mechanisms. The document illustrates the committee’s navigation of these trade-offs, emphasizing harmonized quality standards and pharmacovigilance while considering the economic implications for producers.
Four major stakeholder groups emerge as central to the impacts of the discussions documented: EU regulatory bodies who gain transparency and informed direction; national health authorities tasked with implementation; EU-based herbal medicine producers facing potential adaptation costs; and consumers benefitting from enhanced safety assurances but potentially facing price or availability impacts. For producers, while clearer guidance can reduce uncertainty, compliance and standardization efforts may increase operational costs moderately. Consumers stand to gain through improved product safety, albeit possibly at higher prices or reduced market variety.
As the minutes document deliberations rather than final decisions, this publication marks a continuation in the regulatory process. The EMA and its Herbal Medicinal Products Committee are expected to further refine their positions, and member states’ health authorities will likely evaluate these outcomes as they continue regulatory assessments and potential legislative proposals come forward from European institutions in the near future.
← Atlas › News